In this issue:
FORTE examines optimal induction and maintenance regimens
MM vaccination elicits immunity and durable response in proof-of-principle trial
Low rates of return to work after autologous transplant
MCT1 is a predictive marker for lenalidomide maintenance therapy
Cereblon pathway biomarkers predict post-transplant lenalidomide outcomes
Optimal supportive care with selinexor improves outcomes in RRMM
Greater risk of thrombosis with carfilzomib-containing regimen mitigated with DOAC
Maintenance after salvage transplant prolongs time to disease progression
Daratumumab + ATRA has no activity in daratumumab-refractory MM
Filanesib plus bortezomib/dexamethasone shows promise for RR disease
Please login below to download this issue (PDF)